The neuroprotection exerted by memantine, minocycline and lithium, against neurotoxicity of CSF from patients with amyotrophic lateral sclerosis, is antagonized by riluzole

Neurodegenerative Diseases

Volumn 13, Issue 2-3, 2014, Pages 171-179

  Yáñez, Matilde ^a,d   Matías Guiu, Jorge ^c   Arranz Tagarro, Juan Alberto ^a,d   Galán, Lucía ^c   Viña, Dolores ^d   Gómez Pinedo, Ulises ^c   Vela, Álvaro ^c   Guerrero, Antonio ^c   Martínez Vila, Eduardo ^e   García, Antonio G ^a,b  

^a INSTITUTO TEÓFILO HERNANDO   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Amyotrophic lateral sclerosis; Lithium; Memantine; Minocycline; Neurotoxicity; Riluzole

Indexed keywords

GLUTAMIC ACID; LITHIUM; MEMANTINE; MINOCYCLINE; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CELL DAMAGE; CELL VIABILITY; CEREBROSPINAL FLUID CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOTOR CORTEX; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RAT EMBRYO; ADULT; AGED; BRAIN CELL; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG EFFICACY; EMBRYO; FEMALE; MALE; MOTONEURON; PRIMARY CULTURE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CELL SURVIVAL; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; LITHIUM; MEMANTINE; MINOCYCLINE; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RILUZOLE;

EID: 84896705799     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000357281     Document Type: Article

References (62)

1. Bensimon G, Lacomblez L, Meininger V: A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585-591.
2. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V: Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425-1431.
3. Wang R, Zhang D: Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Neurosci 2005; 22: 2376-2380.
4. Joo IS, Hwang DH, Seok JI, Shin SK, Kim SU: Oral administration of memantine prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Clin Neurol 2007; 3: 181-186.
5. De Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A: A randomized, placebocontrolled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010; 11: 456-460.
6. Kriz J, Nguyen MD, Julien JP: Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002; 10: 268-278.
7. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W: Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002; 13: 1067-1070.
8. Zhu S, Stavrovskaya IG, Drozda M, et al: Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002; 417: 74-78.
9. Zhang W, Narayanan M, Friedlander RM: Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 2003; 53: 267-270.
10. Kriz J, Gowing G, Julien JP: Efficient threedrug cocktail for disease induced by mutant superoxide dismutase. Ann Neurol 2003; 53: 429-436.
11. Gordon PH, Moore DH, Gelinas DF, et al: Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 2004; 62: 1845-1847.
12. Pontieri FE, Ricci A, Pellicano C, Benincasa D, Buttarelli FR: Minocycline in amyotrophic lateral sclerosis: a pilot study. Neurol Sci 2005; 26: 285-287.
13. Gordon PH, Moore DH, Miller RG, et al: Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007; 6: 1045-1053.
14. Shin JH, Cho SI, Lim HR, et al: Concurrent administration of Neu2000 and lithium produces marked improvement of motor neuron survival, motor function, and mortality in a mouse model of amyotrophic lateral sclerosis. Mol Pharmacol 2007; 71: 965-975.
15. Feng HL, Leng Y, Ma CH, Zhang J, Ren M, Chuang DM: Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 2008; 155: 567-572.
16. Fornai F, Longone P, Cafaro L, et al: Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008; 105: 2052-2057.
17. Pizzasegola C, Caron I, Daleno C, et al: Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice. Amyotroph Lateral Scler 2009; 10: 221-228.
18. Gill A, Kidd J, Vieira F, Thompson K, Perrin S: No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS. PLoS One 2009; 4:e6489.
19. Chio A, Borghero G, Calvo A, et al: Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology 2010; 75: 619-625.
20. Verstraete E, Veldink JH, Huisman MH, et al: Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. J Neurol Neurosurg Psychiatry 2012; 83: 557-564.
21. Terro F, Lesort M, Dussartre C, Barthe D, Hugon J: Phosphorylated neurofilament expression and resistance to kainate toxicity. Brain Res Bull 1996; 41: 231-235.
22. Shaw PJ, Eggett CJ: Molecular factors underlying selective vulnerability of motor neurons to neurodegeneration in amyotrophic lateral sclerosis. J Neurol 2000; 247(suppl 1):I17-I27.
23. Shahani N, Gourie-Devi M, Nalini A, Raju TR: Cyclophosphamide attenuates the degenerative changes induced by CSF from patients with amyotrophic lateral sclerosis in the neonatal rat spinal cord. J Neurol Sci 2001; 185: 109-118.
24. Sen I, Nalini A, Joshi NB, Joshi PG: Cerebrospinal fluid from amyotrophic lateral sclerosis patients preferentially elevates intracellular calcium and toxicity in motor neurons via AMPA/kainate receptor. J Neurol Sci 2005; 235: 45-54.
25. Shahani N, Gourie-Devi M, Nalini A, et al: (-)-Deprenyl alleviates the degenerative changes induced in the neonatal rat spinal cord by CSF from amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 172-179.
26. Anneser JM, Chahli C, Borasio GD: Protective effect of metabotropic glutamate receptor inhibition on amyotrophic lateral sclerosiscerebrospinal fluid toxicity in vitro. Neuroscience 2006; 141: 1879-1886.
27. Gunasekaran R, Narayani RS, Vijayalakshmi K, et al: Exposure to cerebrospinal fluid of sporadic amyotrophic lateral sclerosis patients alters Nav1.6 and Kv1.6 channel expression in rat spinal motor neurons. Brain Res 2009; 1255: 170-179.
28. Orallo F: Trans-resveratrol: a magical elixir of eternal youth? Curr Med Chem 2008; 15: 1887-1898.
29. Yáñez M, Galán L, Matias-Guiu J, Vela A, Guerrero A, García AG: CSF from amyotrophic lateral sclerosis patients produces glutamate independent death of rat motor brain cortical neurons: protection by resveratrol but not riluzole. Brain Res 2011; 1423: 77-86.
30. Meininger V: European ALS Consortium. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5(suppl 1):133-134.
31. Lanka V, Cudkowicz M: Therapy development for ALS: lessons learned and path forward. Amyotroph Lateral Scler 2008; 9: 131-140.
32. Rodriguez de Rivera FJ, Grande M, Garcia-Caballero J, et al: Development of a clinical pathway for the attention of patients with amyotrophic lateral sclerosis in a regional network. ALS Assistance Network-Comunidad de Madrid (in Spanish). Neurologia 2007; 22: 354-361.
33. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
34. Vijayalakshmi K, Alladi PA, Ghosh S, et al: Evidence of endoplasmic reticular stress in the spinal motor neurons exposed to CSF from sporadic amyotrophic lateral sclerosis patients. Neurobiol Dis 2011; 41: 695-705.
35. Vijayalakshmi K, Alladi PA, Sathyaprabha TN, Subramaniam JR, Nalini A, Raju TR: Cerebrospinal fluid from sporadic amyotrophic lateral sclerosis patients induces degeneration of a cultured motor neuron cell line. Brain Res 2009; 1263: 122-133.
36. Kulshreshtha D, Vijayalakshmi K, Alladi PA, Sathyaprabha TN, Nalini A, Raju TR: Vascular endothelial growth factor attenuates neurodegenerative changes in the NSC-34 motor neuron cell line induced by cerebrospinal fluid of sporadic amyotrophic lateral sclerosis patients. Neurodegener Dis 2011; 8: 322-330.
37. Hof PR, Perl DP: Neurofibrillary tangles in the primary motor cortex in Guamanian amyotrophic lateral sclerosis/parkinsonismdementia complex. Neurosci Lett 2002; 328: 294-298.
38. Fernandez-Santiago R, Hoenig S, Lichtner P, et al: Identification of novel angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis. J Neurol 2009; 256: 1337-1342.
39. Shobha K, Vijayalakshmi K, Alladi PA, Nalini A, Sathyaprabha TN, Raju TR: Altered in-vitro and in-vivo expression of glial glutamate transporter-1 following exposure to cerebrospinal fluid of amyotrophic lateral sclerosis patients. J Neurol Sci 2007; 254: 9-16.
40. Ramamohan PY, Gourie-Devi M, Nalini A, et al: Cerebrospinal fluid from amyotrophic lateral sclerosis patients causes fragmentation of the Golgi apparatus in the neonatal rat spinal cord. Amyotroph Lateral Scler 2007; 8: 79-82.
41. Sankaranarayani R, Nalini A, Rao Laxmi T, Raju TR: Altered neuronal activities in the motor cortex with impaired motor performance in adult rats observed after infusion of cerebrospinal fluid from amyotrophic lateral sclerosis patients. Behav Brain Res 2010; 206: 109-119.
42. Chen-Roetling J, Chen L, Regan RF: Minocycline attenuates iron neurotoxicity in cortical cell cultures. Biochem Biophys Res Commun 2009; 386: 322-326.
43. Jorda EG, Verdaguer E, Canudas AM, et al: Implication of cyclin-dependent kinase 5 in the neuroprotective properties of lithium. Neuroscience 2005; 134: 1001-1011.
44. Volbracht C, van Beek J, Zhu C, Blomgren K, Leist M: Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur J Neurosci 2006; 23: 2611-2622.
45. Peluffo H, Estevez A, Barbeito L, Stutzmann JM: Riluzole promotes survival of rat motoneurons in vitro by stimulating trophic activity produced by spinal astrocyte monolayers. Neurosci Lett 1997; 228: 207-211.
46. Arce MP, Rodriguez-Franco MI, Gonzalez-Munoz GC, et al: Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease. J Med Chem 2009; 52: 7249-7257.
47. Arias E, Ales E, Gabilan NH, et al: Galantamine prevents apoptosis induced by betaamyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 2004; 46: 103-114.
48. Arias E, Gallego-Sandin S, Villarroya M, Garcia AG, Lopez MG: Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J Pharmacol Exp Ther 2005; 315: 1346-1353.
49. Bond M, Rogers G, Peters J, et al: The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No 111): a systematic review and economic model. Health Technol Assess 2012; 16: 1-470.
50. 2+ levels in IMR32 neuroblastoma cells. Arch Toxicol 2001; 75: 214-220.
51. 2+ increase in human osteosarcoma cells. Pharmacology 2002; 66: 120-127.
52. 2+ movement and cytotoxicity in Madin-Darby canine kidney cells. Hum Exp Toxicol 2006; 25: 461-469.
53. Akamatsu K, Shibata MA, Ito Y, Sohma Y, Azuma H, Otsuki Y: Riluzole induces apoptotic cell death in human prostate cancer cells via endoplasmic reticulum stress. Anticancer Res 2009; 29: 2195-2204.
54. Caumont AS, Octave JN, Hermans E: Specific regulation of rat glial cell line-derived neurotrophic factor gene expression by riluzole in C6 glioma cells. J Neurochem 2006; 97: 128-139.
55. Mizuta I, Ohta M, Ohta K, Nishimura M, Mizuta E, Kuno S: Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci Lett 2001; 310: 117-120.
56. Katoh-Semba R, Takeuchi IK, Inaguma Y, et al: Induction of brain-derived neurotrophic factor by convulsant drugs in the rat brain: involvement of region-specific voltage-dependent calcium channels. J Neurochem 2001; 77: 71-83.
57. Milane A, Tortolano L, Fernandez C, Bensimon G, Meininger V, Farinotti R: Brain and plasma riluzole pharmacokinetics: effect of minocycline combination. J Pharm Pharm Sci 2009; 12: 209-217.
58. Bellingham MC: A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther 2010; 17: 4-31.
59. Meininger V, Bensimon G, Bradley WR, et al: Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 107-117.
60. Rowland LP: Riluzole for the treatment of amyotrophic lateral sclerosis-too soon to tell? N Engl J Med 1994; 330: 636-637.
61. Rowland LP, Shneider NA: Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688-1700.
62. Meininger V: Clinical trials in ALS: what did we learn from recent trials in humans? Neurodegener Dis 2005; 2: 208-214.